FR08C0015I1 - - Google Patents

Info

Publication number
FR08C0015I1
FR08C0015I1 FR08C0015C FR08C0015I1 FR 08C0015 I1 FR08C0015 I1 FR 08C0015I1 FR 08C0015 C FR08C0015 C FR 08C0015C FR 08C0015 I1 FR08C0015 I1 FR 08C0015I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25544691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR08C0015(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR08C0015I1 publication Critical patent/FR08C0015I1/fr
Application granted granted Critical
Publication of FR08C0015I2 publication Critical patent/FR08C0015I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
FR08C0015C 1997-12-24 2008-04-17 Dérivés de sulfamides en tant que prodrogues d'inhibiteurs de protéase d'aspartyl Active FR08C0015I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/998,050 US6436989B1 (en) 1997-12-24 1997-12-24 Prodrugs of aspartyl protease inhibitors

Publications (2)

Publication Number Publication Date
FR08C0015I1 true FR08C0015I1 (cs) 2008-05-30
FR08C0015I2 FR08C0015I2 (fr) 2009-10-30

Family

ID=25544691

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0015C Active FR08C0015I2 (fr) 1997-12-24 2008-04-17 Dérivés de sulfamides en tant que prodrogues d'inhibiteurs de protéase d'aspartyl

Country Status (42)

Country Link
US (5) US6436989B1 (cs)
EP (2) EP1944300A3 (cs)
JP (3) JP3736964B2 (cs)
KR (1) KR100520737B1 (cs)
CN (2) CN101565412A (cs)
AP (1) AP1172A (cs)
AR (1) AR017965A1 (cs)
AT (1) ATE382042T1 (cs)
AU (1) AU755087B2 (cs)
BG (1) BG64869B1 (cs)
BR (1) BR9814480A (cs)
CA (1) CA2231700C (cs)
CO (1) CO4990992A1 (cs)
CZ (1) CZ301653B6 (cs)
DE (2) DE122008000021I2 (cs)
DK (1) DK0933372T3 (cs)
EA (1) EA003509B1 (cs)
EE (1) EE04466B1 (cs)
ES (1) ES2299193T3 (cs)
FR (1) FR08C0015I2 (cs)
HU (2) HU229596B1 (cs)
ID (1) ID24962A (cs)
IL (2) IL136941A0 (cs)
IS (1) IS2817B (cs)
LU (1) LU91426I2 (cs)
ME (1) MEP82008A (cs)
MY (1) MY131525A (cs)
NL (1) NL300339I2 (cs)
NO (2) NO326265B1 (cs)
NZ (1) NZ505776A (cs)
OA (1) OA11468A (cs)
PE (1) PE20000048A1 (cs)
PL (1) PL202845B1 (cs)
PT (1) PT933372E (cs)
RS (1) RS52483B (cs)
SI (1) SI0933372T1 (cs)
SK (1) SK287123B6 (cs)
TR (1) TR200002615T2 (cs)
TW (1) TW486474B (cs)
UA (1) UA72733C2 (cs)
WO (1) WO1999033815A1 (cs)
ZA (1) ZA9811830B (cs)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
TR200003513T2 (tr) 1998-06-02 2001-06-21 Osi Pharmaceuticals, Inc. Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
WO2000018384A2 (en) * 1998-09-28 2000-04-06 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic acid isopropyl ester and amprenavir
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
CN100369904C (zh) 2001-02-14 2008-02-20 泰博特克药品有限公司 2-(取代-氨基)-苯并噻唑磺酰胺hiv蛋白酶抑制剂
CA2442870C (en) 2001-04-09 2011-08-02 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
DE60232067D1 (de) 2001-05-11 2009-06-04 Tibotec Pharm Ltd 2-amino-benzoxazol-suphonamide als breitspektrum-hiv-protease-inhibitoren
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
EP1450811B1 (en) 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
AR037797A1 (es) * 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
DE60236458D1 (de) 2001-12-20 2010-07-01 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
KR20040068317A (ko) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
MXPA04006201A (es) 2001-12-21 2004-12-06 Tibotec Pharm Ltd Sulfonamidas que contienen fenilo sustituido con grupos heterociclicos, inhibidores de la proteasa del vih de amplio espectro.
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
AU2003231765B9 (en) * 2002-04-26 2010-01-28 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
KR20100130234A (ko) 2002-05-17 2010-12-10 티보텍 파마슈티컬즈 광범위 스펙트럼의 치환된 벤즈이속사졸 설폰아미드 ｈｉｖ 프로테아제 저해제
US7199148B2 (en) 2002-08-14 2007-04-03 Tibotec Pharmaceuticals Ltd Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2425031A1 (en) * 2003-04-01 2004-10-01 Smithkline Beecham Corporation Pharmaceutical compositions
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
MXPA05011296A (es) 2003-04-25 2006-01-24 Gilead Sciences Inc Conjugados de fosfonato inhibidores de la cinasa.
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
EP1628685B1 (en) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
EP2295404A3 (en) 2003-07-09 2011-05-11 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP4738333B2 (ja) * 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド ９−アミノメチルテトラサイクリン化合物のプロドラッグ
US20050119163A1 (en) 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US8193227B2 (en) 2003-12-11 2012-06-05 Abbott Laboratories HIV protease inhibiting compounds
US7834043B2 (en) * 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
RS52883B (en) * 2003-12-15 2014-02-28 Merck Sharp & Dohme Corp. HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS
US7799772B2 (en) 2003-12-18 2010-09-21 Janssen Pharmaceutica N.V. Pyrido-and pyrimidopyrimidine derivatives as anti-profilerative agents
US7432272B2 (en) 2003-12-22 2008-10-07 Gilead Sciences, Inc. Antiviral analogs
NZ552276A (en) * 2004-07-06 2011-03-31 Abbott Lab Prodrugs of HIV protease inhibitors
US7871991B2 (en) 2004-07-27 2011-01-18 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
ES2319996T3 (es) 2004-08-02 2009-05-18 Ambrilia Biopharma Inc. Compuestos basados en lisina.
RU2379312C2 (ru) * 2004-08-02 2010-01-20 Амбрилиа Байофарма Инк. Соединения на основе лизина, фармацевтическая композиция, содержащая эти соединения, применение указанных соединений для лечения или профилактики вич инфекции
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
WO2006024488A2 (en) 2004-08-30 2006-03-09 Interstitial Therapeutics Medical stent provided with inhibitors of atp synthesis
WO2006058905A1 (en) 2004-12-01 2006-06-08 Devgen Nv 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
EP1969940A3 (en) 2004-12-17 2008-12-10 Devgen NV Nematicidal compositions
KR101278397B1 (ko) * 2005-01-19 2013-06-25 리겔 파마슈티칼스, 인크. 2,4-피리미딘디아민 화합물의 전구약물 및 이의 용도
WO2006104646A1 (en) * 2005-03-11 2006-10-05 Smithkline Beecham Corporation Hiv protease inhibitors
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
ES2539527T3 (es) * 2005-04-27 2015-07-01 Taimed Biologics, Inc. Método para mejorar la farmacocinética de los inhibidores de las proteasas y de los precursores de los inhibidores de las proteasas
EP1940856B1 (en) 2005-10-21 2014-10-08 Universiteit Antwerpen Novel urokinase inhibitors
AR058238A1 (es) 2005-11-28 2008-01-23 Tibotec Pharm Ltd Compuestos y derivados de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
AR057182A1 (es) 2005-11-28 2007-11-21 Tibotec Pharm Ltd Compuestos de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
CA2632095A1 (en) * 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
SI1968990T1 (sl) 2005-12-27 2015-05-29 Otsuka Pharmaceutical Co., Ltd. Vodotopna benzoazepiska spojina in njen farmacevtski sestavek
CA2654583C (en) 2006-07-13 2015-11-24 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
RU2009112716A (ru) 2006-09-08 2010-10-20 Байер Шеринг Фарма Акциенгезельшафт (DE) Соединения и способы для агентов, меченых 18f
CN102083793A (zh) 2006-09-21 2011-06-01 安布林生物制药公司 蛋白酶抑制剂
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
JP5448854B2 (ja) * 2007-03-12 2014-03-19 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー−プロテアーゼ阻害剤複合体
CA2693715C (en) 2007-07-27 2015-10-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
EP2053033A1 (en) 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
EP2283024B1 (en) 2008-03-10 2013-05-15 Janssen Pharmaceutica, N.V. 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
EP2116236A1 (en) 2008-04-21 2009-11-11 Université de Mons-Hainaut Bisbenzamidine derivatives for use as antioxidant
CA2729769C (en) 2008-07-08 2017-09-05 Gilead Sciences, Inc. Salts of hiv inhibitor compounds
TWI557117B (zh) 2008-12-09 2016-11-11 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
WO2010134045A1 (en) * 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
AU2010296846B2 (en) 2009-09-16 2013-11-28 Sun Pharmaceutical Industries Limited Process for the preparation of fosamprenavir calcium
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
US20120232640A1 (en) 2009-11-19 2012-09-13 Blue Medical Devices Bv Narrow profile composition-releasing expandable medical balloon catheter
WO2011085130A1 (en) 2010-01-07 2011-07-14 Pliva Hrvatska D.O.O. Solid state forms of fosamprenavir calcium salt and process for preparation thereof
EP3127542B1 (en) 2010-01-27 2018-08-22 VIIV Healthcare Company Antiviral therapy
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (en) 2010-03-19 2011-09-22 Lupin Limited Ammonium, calcium and tris salts of fosamprenavir
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
US20130211108A1 (en) 2010-06-18 2013-08-15 Mylan Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
WO2012032389A2 (en) 2010-09-10 2012-03-15 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
GB201019043D0 (en) 2010-11-10 2010-12-22 Protea Biopharma N V Use of 2',5'-oligoadenylate derivative compounds
WO2012085625A1 (en) 2010-12-21 2012-06-28 Lupin Limited Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
WO2012107937A2 (en) * 2011-02-10 2012-08-16 Mylan Laboratories Ltd Crystalline fosamprenavir calcium and process for the preparation thereof"
JP6110372B2 (ja) 2011-06-21 2017-04-05 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アンジオポエチン様３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物及びその使用方法
EP2723390B1 (en) 2011-06-23 2017-12-27 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
US9309213B2 (en) 2011-07-11 2016-04-12 Purdue Research Foundation C-3 substituted bicyclooctane based HIV protease inhibitors
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
US9233943B2 (en) 2012-01-10 2016-01-12 Council Of Scientific & Industrial Research Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
EP2700396A3 (en) 2012-06-20 2015-04-29 Sylphar Nv Strip for the delivery of oral care compositions
WO2014059034A2 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
JP2015536940A (ja) 2012-10-29 2015-12-24 シプラ・リミテッド 抗ウイルス性ホスホネート類似体及びその製造方法
DK2929031T5 (da) 2012-12-05 2021-08-23 Alnylam Pharmaceuticals Inc Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
EP3312281A3 (en) 2013-03-14 2018-06-27 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
EP3828276A1 (en) 2013-05-22 2021-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
PE20210921A1 (es) 2013-05-22 2021-05-19 Alnylam Pharmaceuticals Inc Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden
AU2014362262B2 (en) 2013-12-12 2021-05-13 Alnylam Pharmaceuticals, Inc. Complement component iRNA compositions and methods of use thereof
CA2938857A1 (en) 2014-02-11 2015-08-20 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk) irna compositions and methods of use thereof
TW201607559A (zh) 2014-05-12 2016-03-01 阿尼拉製藥公司 治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
CN112301031A (zh) 2014-05-22 2021-02-02 阿尔尼拉姆医药品有限公司 血管紧张素原(AGT)iRNA组合物及其使用方法
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
MX2017000026A (es) 2014-07-11 2017-05-01 Gilead Sciences Inc Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
WO2016061487A1 (en) 2014-10-17 2016-04-21 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
EP3212794B1 (en) 2014-10-30 2021-04-07 Genzyme Corporation Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
CA2968114A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
WO2016083490A1 (en) 2014-11-27 2016-06-02 Remynd Nv Compounds for the treatment of amyloid-associated diseases
AU2016219263B2 (en) 2015-02-13 2022-12-01 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
TWI723986B (zh) 2015-04-13 2021-04-11 美商阿尼拉製藥公司 類血管生成素３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物及其用途方法
DK3288637T3 (da) 2015-04-28 2022-10-17 Newsouth Innovations Pty Ltd Målretning af nad+ til behandling af kemoterapi- og radioterapi-induceret, kognitiv funktionsnedsættelse, neuropatier og inaktivitet
EA201792444A1 (ru) 2015-05-06 2018-06-29 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ФАКТОРА XII (ФАКТОРА ХАГЕМАНА) (F12), ПЛАЗМЕННОГО КАЛЛИКРЕИНА B (ФАКТОРА ФЛЕТЧЕРА) 1 (KLKB1) И КИНИНОГЕНА 1 (KNG1) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP3310918B1 (en) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
EP3350328A1 (en) 2015-09-14 2018-07-25 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
JP2018527366A (ja) 2015-09-15 2018-09-20 ギリアード サイエンシーズ， インコーポレイテッド ＨＩＶを処置するためのｔｏｌｌ様レセプターのモジュレーター
CA3007014A1 (en) 2015-12-07 2017-06-15 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a serpinc1-associated disorder
WO2017100542A1 (en) 2015-12-10 2017-06-15 Alnylam Pharmaceuticals, Inc. Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
US20190256845A1 (en) 2016-06-10 2019-08-22 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
TW202313978A (zh) 2016-11-23 2023-04-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
JP7058656B2 (ja) 2016-12-16 2022-04-22 アルナイラム ファーマシューティカルズ， インコーポレイテッド トランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物を用いてＴＴＲ関連疾患を治療または予防するための方法
EA201992397A1 (ru) 2017-05-11 2020-03-16 Реминд Н.В. Соединения для лечения эпилепсии, нейродегенеративных нарушений и других нарушений цнс
WO2018206757A1 (en) 2017-05-11 2018-11-15 Remynd N.V. Inhibitors of pde6delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders
TWI843703B (zh) 2017-07-10 2024-06-01 美商健贊公司 於患有血友病之個體中治療出血事件之方法及組成物
AU2018304591A1 (en) 2017-07-21 2020-03-05 Janssen Sciences Ireland Unlimited Company Regimens for treating hiv infections and aids
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
EP3704252A1 (en) 2017-11-01 2020-09-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
AU2019321375A1 (en) 2018-08-13 2021-03-11 Alnylam Pharmaceuticals, Inc. Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
JP2022517270A (ja) 2019-01-16 2022-03-07 ジェンザイム・コーポレーション Ｓｅｒｐｉｎｃ１ ｉＲＮＡ組成物およびその使用方法
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
MX2022010413A (es) 2020-02-24 2022-09-07 Univ Leuven Kath Compuestos de pirrolopiridina e imidazopiridina antivirales.
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
JP2024500543A (ja) 2020-12-22 2024-01-09 ルクセンブルク インスティテュート オブ ヘルス（エルアイエイチ） がん及び循環器疾患の処置のための選択的ａｃｋｒ３調節物質としてのコノリジンアナログ
EP4301369A1 (en) 2021-03-04 2024-01-10 Universiteit Antwerpen Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer
CN117500772A (zh) 2021-05-31 2024-02-02 泰利克斯制药(创新)私人有限公司 改进的前列腺特异性膜抗原靶向放射性药物及其用途
EP4387629A1 (en) 2021-08-18 2024-06-26 Katholieke Universiteit Leuven KU Leuven Research & Development 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues
EP4405357A1 (en) 2021-09-23 2024-07-31 Katholieke Universiteit Leuven KU Leuven Research & Development Ribonucleoside analogues against -sars-cov-2
WO2023241799A1 (en) 2022-06-15 2023-12-21 Université Libre de Bruxelles Flavanols for use in the treatment of retroviral infections
WO2024062043A1 (en) 2022-09-21 2024-03-28 Universiteit Antwerpen Substituted phenothiazines as ferroptosis inhibitors
WO2024175804A1 (en) 2023-02-24 2024-08-29 Katholieke Universiteit Leuven Nuclear transport modulators
WO2025104221A1 (en) 2023-11-15 2025-05-22 Université Libre de Bruxelles Uses of protein tyrosine phosphatase receptor kappa inhibitors
WO2025157901A1 (en) 2024-01-26 2025-07-31 Aneurotech Bv Piperidine carboxamide fatty acid prodrugs

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743722A (en) 1971-07-14 1973-07-03 Abbott Lab Anti-coagulant isolation
FR2459235A1 (fr) 1979-06-14 1981-01-09 Sanofi Sa Nouveaux derives de sulfonyl-aniline, leur procede de preparation et leur application therapeutique
JPS5946252A (ja) 1982-09-09 1984-03-15 Dainippon Ink & Chem Inc 含フツ素アミノカルボキシレ−トおよびその製法
JPS5948449A (ja) 1982-09-13 1984-03-19 Dainippon Ink & Chem Inc 直鎖状含フツ素アニオン化合物およびその製造方法
JPS6171830A (ja) 1984-09-17 1986-04-12 Dainippon Ink & Chem Inc 界面活性剤組成物
US4616088A (en) 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4629724A (en) 1984-12-03 1986-12-16 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitors
DE3635907A1 (de) 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
GB2200115B (en) 1987-01-21 1990-11-14 Sandoz Ltd Novel peptide derivatives, their production and use
CA1340588C (en) 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
WO1990007330A1 (en) 1989-01-06 1990-07-12 The Regents Of The University Of California Selection method for specific useful pharmaceutical compounds
US5151438A (en) 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
IE902295A1 (en) 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
JPH07502970A (ja) 1990-06-01 1995-03-30 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー １，４―ジアミノ―２，３―ジヒドロキシブタン類
TW225540B (cs) 1990-06-28 1994-06-21 Shionogi & Co
DK0554400T3 (da) 1990-11-19 1998-02-16 Monsanto Co Retrovirale proteaseinhibitorer
ATE136888T1 (de) 1990-11-19 1996-05-15 Monsanto Co Retrovirale proteaseinhibitoren
ES2151975T3 (es) 1990-11-19 2001-01-16 Monsanto Co Inhibidores de proteasas retroviricas.
WO1992008688A1 (en) 1990-11-19 1992-05-29 Monsanto Company Retroviral protease inhibitors
IE20010533A1 (en) 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
DK0541168T3 (da) 1991-11-08 1998-05-11 Merck & Co Inc HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
DK0641333T3 (da) 1992-05-20 1996-09-02 Monsanto Co Fremgangsmåde til fremstilling af mellemprodukter, som er anvendelige ved syntese af retrovirus- protease-inhibitorer
ES2155069T3 (es) 1992-05-21 2001-05-01 Monsanto Co Inhibidores de proteasas retrovirales.
JP4091653B2 (ja) 1992-08-25 2008-05-28 ジー．ディー．サール、リミテッド、ライアビリティ、カンパニー レトロウイルスプロテアーゼ阻害剤として有用なｎ−（アルカノイルアミノ−２−ヒドロキシプロピル）スルホンアミド
EP0656887B1 (en) 1992-08-25 1998-10-28 G.D. Searle & Co. Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
CA2140928C (en) 1992-08-25 2008-01-29 Michael L. Vazquez Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
CA2120956A1 (en) * 1992-09-03 1994-03-17 Franz Esser New amino acid derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
TW372972B (en) 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
ATE183499T1 (de) 1992-10-30 1999-09-15 Searle & Co Sulfonylalkanoylaminohydroxyethylaminosulfamins uren verwendbar als inhibitoren retroviraler proteasen
PT810208E (pt) 1992-10-30 2002-06-28 Searle & Co Derivados do acido hidroxietilamino-sulfamico n-substituido uteis como inibidores de proteases retrovrais
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
WO1994018192A1 (en) 1993-02-12 1994-08-18 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
TW281669B (cs) 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
AU7669794A (en) 1993-08-24 1995-03-21 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
IL110898A0 (en) 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
IL111584A0 (en) 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
US5527829A (en) 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE19506742A1 (de) 1995-02-27 1996-08-29 Bayer Ag Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
US5691372A (en) 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5750493A (en) 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US5646180A (en) 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
KR20010033595A (ko) * 1997-12-24 2001-04-25 버텍스 파마슈티칼스 인코포레이티드 아스파틸 프로테아제 억제제의 전구약물
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
CO5261510A1 (es) * 1999-02-12 2003-03-31 Vertex Pharma Inhibidores de aspartil proteasa

Also Published As

Publication number Publication date
EA003509B1 (ru) 2003-06-26
EP0933372B1 (en) 2007-12-26
YU39800A (sh) 2004-03-12
CZ301653B6 (cs) 2010-05-12
SI0933372T1 (sl) 2008-06-30
CZ20002363A3 (cs) 2000-11-15
EE04466B1 (et) 2005-04-15
IL136941A (en) 2006-06-11
DE69838903T2 (de) 2008-09-18
SK9662000A3 (en) 2001-02-12
CA2231700C (en) 2005-08-09
NO2009008I1 (cs) 2009-05-04
OA11468A (en) 2004-05-05
JPH11209337A (ja) 1999-08-03
NZ505776A (en) 2003-06-30
SK287123B6 (sk) 2009-12-07
JP2009102400A (ja) 2009-05-14
EP1944300A2 (en) 2008-07-16
PL202845B1 (pl) 2009-07-31
MEP82008A (en) 2011-12-20
CN100503589C (zh) 2009-06-24
WO1999033815A1 (en) 1999-07-08
AU6546698A (en) 1999-07-19
ATE382042T1 (de) 2008-01-15
HU229596B1 (en) 2014-02-28
JP2005350478A (ja) 2005-12-22
CN1284071A (zh) 2001-02-14
HUS1400042I1 (hu) 2017-06-28
JP4282639B2 (ja) 2009-06-24
NO326265B1 (no) 2008-10-27
BG104631A (en) 2001-02-28
LU91426I2 (fr) 2008-06-02
US20100124543A1 (en) 2010-05-20
ID24962A (id) 2000-08-31
HK1021737A1 (en) 2000-06-30
AP2000001850A0 (en) 2000-06-30
PE20000048A1 (es) 2000-02-08
US6838474B2 (en) 2005-01-04
AP1172A (en) 2003-06-30
ME00561B (me) 2011-10-10
BR9814480A (pt) 2001-09-25
HUP0101831A3 (en) 2002-08-28
AR017965A1 (es) 2001-10-24
IL136941A0 (en) 2001-06-14
PL342113A1 (en) 2001-05-21
DE69838903D1 (de) 2008-02-07
UA72733C2 (en) 2005-04-15
CA2231700A1 (en) 1999-06-24
TW486474B (en) 2002-05-11
US7592368B2 (en) 2009-09-22
EE200000385A (et) 2001-12-17
RS52483B (en) 2013-02-28
NL300339I2 (nl) 2009-11-02
IS2817B (is) 2012-11-15
LU91426I9 (cs) 2018-12-28
CN101565412A (zh) 2009-10-28
US6436989B1 (en) 2002-08-20
US20030207871A1 (en) 2003-11-06
US6559137B1 (en) 2003-05-06
DE122008000021I1 (de) 2008-08-14
BG64869B1 (bg) 2006-07-31
ES2299193T3 (es) 2008-05-16
US20050148548A1 (en) 2005-07-07
MY131525A (en) 2007-08-30
AU755087B2 (en) 2002-12-05
NO2009008I2 (cs) 2010-09-27
KR100520737B1 (ko) 2005-10-12
DE122008000021I2 (de) 2010-02-04
EP1944300A3 (en) 2008-11-05
NO20003304L (no) 2000-08-21
NL300339I1 (nl) 2008-06-02
TR200002615T2 (tr) 2001-01-22
NO20003304D0 (no) 2000-06-23
IS5546A (is) 2000-06-22
FR08C0015I2 (fr) 2009-10-30
PT933372E (pt) 2008-03-31
JP3736964B2 (ja) 2006-01-18
KR20010033600A (ko) 2001-04-25
CO4990992A1 (es) 2000-12-26
HUP0101831A2 (hu) 2002-04-29
ZA9811830B (en) 2000-06-23
EP0933372A1 (en) 1999-08-04
DK0933372T3 (da) 2008-04-28
EA200000703A1 (ru) 2000-12-25

Similar Documents

Publication Publication Date Title
NO2009008I1 (cs)
CH0944937H2 (cs)
ITMI971012A0 (cs)
IN190966B (cs)
ITMI971042A0 (cs)
ITVI970030V0 (cs)
ITMI970471V0 (cs)
ITMI971165A0 (cs)
ITAR970020A0 (cs)
ITMI971253A0 (cs)
ITMI971281A0 (cs)
ITTO970094V0 (cs)
ITVR970026V0 (cs)
ITVR970014V0 (cs)
ITVE970027V0 (cs)
CN3057613S (cs)
CN3056875S (cs)
CN3057977S (cs)
CN3058025S (cs)
CN3057976S (cs)
CN3057730S (cs)
CN3057614S (cs)
CN3058088S (cs)
CN3058057S (cs)
CN3057436S (cs)